Roivant And Immunovant Say Topline Results From Period 1 Of Proof-of-concept Trial of IMVT-1402 (Imeroprubart) For Cutaneous Lupus Erythematosus Did Not Achieve Statistical Significance On The Primary Endpoint

Immunovant's proof-of-concept trial for IMVT-1402 (imeroprubart) in cutaneous lupus erythematosus did not achieve statistical significance on its primary endpoint, the CLASI-A percent change from baseline at Week 12. While positive trends were noted in multiple endpoints and the drug showed a favorable safety profile, the results did not meet the company's criteria to continue development in this indication. All other clinical development timelines for Immunovant remain on track.